A Phase I Study of BYL719 and Trastuzumab-MCC-DM1 in HER2-Positive Metastatic Breast Cancer Patients With Progression on Prior Trastuzumab and Taxane-Based Therapy

Trial Profile

A Phase I Study of BYL719 and Trastuzumab-MCC-DM1 in HER2-Positive Metastatic Breast Cancer Patients With Progression on Prior Trastuzumab and Taxane-Based Therapy

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Alpelisib (Primary) ; Trastuzumab emtansine (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Results (data cut off date: 1 Jan, 2017) assessing the maximum tolerated dose, safety, and activity of alpelisib with ado-trastuzumab in patients with in HER2-positive metastatic breast cancer, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 13 Apr 2017 Planned End Date changed from 1 Nov 2017 to 1 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top